Fennec Pharmaceuticals Inc
NASDAQ:FENC
Intrinsic Value
Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. [ Read More ]
The intrinsic value of one FENC stock under the Base Case scenario is 29.1 USD. Compared to the current market price of 9.16 USD, Fennec Pharmaceuticals Inc is Undervalued by 69%.
Valuation Backtest
Fennec Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling FENC stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Fennec Pharmaceuticals Inc
| Current Assets | 26.9m |
| Cash & Short-Term Investments | 13.3m |
| Receivables | 8.8m |
| Other Current Assets | 4.8m |
| Non-Current Assets | 6k |
| Other Non-Current Assets | 6k |
| Current Liabilities | 7.6m |
| Accounts Payable | 3.8m |
| Accrued Liabilities | 3.8m |
| Non-Current Liabilities | 30.9m |
| Long-Term Debt | 30m |
| Other Non-Current Liabilities | 933k |
Earnings Waterfall
Fennec Pharmaceuticals Inc
|
Revenue
|
21.3m
USD
|
|
Cost of Revenue
|
-1.3m
USD
|
|
Gross Profit
|
20m
USD
|
|
Operating Expenses
|
-32.8m
USD
|
|
Operating Income
|
-12.8m
USD
|
|
Other Expenses
|
-3.3m
USD
|
|
Net Income
|
-16m
USD
|
Free Cash Flow Analysis
Fennec Pharmaceuticals Inc
FENC Profitability Score
Profitability Due Diligence
Fennec Pharmaceuticals Inc's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Score
Fennec Pharmaceuticals Inc's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
FENC Solvency Score
Solvency Due Diligence
Fennec Pharmaceuticals Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Fennec Pharmaceuticals Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FENC Price Targets Summary
Fennec Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for FENC is 18.7 USD with a low forecast of 16.16 USD and a high forecast of 23.1 USD.
Ownership
FENC Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
FENC Price
Fennec Pharmaceuticals Inc
| Average Annual Return | 34.96% |
| Standard Deviation of Annual Returns | 65.72% |
| Max Drawdown | -27% |
| Market Capitalization | 247.6m USD |
| Shares Outstanding | 27 099 900 |
| Percentage of Shares Shorted | 9.47% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Durham, North Carolina and currently employs 10 full-time employees. The company went IPO on 2001-06-05. The firm is focused on the development of PEDMARK for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The Company’s only product candidate in the clinical-stage of development is PEDMARK. The company announced two results of Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children, including the pivotal Phase III study SIOPEL 6 and the proof-of-concept Phase III study in collaboration with the Children’s Oncology Group (COG ACCL0431). PEDMARK has the potential to reduce the incidence and/or grade of chemotherapy-induced hearing loss. The Company’s four subsidiaries includes Oxiquant, Inc. and Fennec Pharmaceuticals, Inc., both Delaware corporations, Cadherin Biomedical Inc., a Canadian company, and Fennec Pharmaceuticals (EU) Limited (Fennec Limited), an Ireland company. Apart from Fennec Pharmaceuticals, Inc., all subsidiaries are inactive.
Contact
IPO
Employees
Officers
The intrinsic value of one FENC stock under the Base Case scenario is 29.1 USD.
Compared to the current market price of 9.16 USD, Fennec Pharmaceuticals Inc is Undervalued by 69%.
You don't have any saved screeners yet
